MedPath

Using Exercise and Electrical Brain Stimulation to Improve Memory in Dementia

Not Applicable
Recruiting
Conditions
Mild Cognitive Impairment
Alzheimer Disease
Interventions
Other: tDCS
Other: Sham tDCS
Other: Exercise
Other: Exercise Education
Registration Number
NCT03670615
Lead Sponsor
Sunnybrook Health Sciences Centre
Brief Summary

Mild cognitive impairment and Alzheimer's disease are conditions that involve memory difficulties. Transcranial direct current stimulation is a type of brain stimulation. It may help improve these memory difficulties. However, it works better on active brain areas. This study looks at if combining exercise and applying current to important parts of the brain can help improve memory in people with Mild Cognitive Impairment or Alzheimer's disease.

Detailed Description

Objectives: To assess the efficacy of a combined exercise and tDCS treatment for improving cognitive outcomes in mild cognitive impairment and mild Alzheimer's disease.

Study Design: Eligible participants will be randomized to one of three interventions: Exercise and tDCS, Treatment as usual (TAU/exercise education) and tDCS, or Exercise and sham tDCS. Participants randomized to an exercise group will undergo exercise, followed by either sham or active tDCS. Participants randomized to TAU will receive written information in accordance with the Canadian Physical Activity Guidelines for older adults and tDCS for the same duration. Cognition, neuropsychiatric symptoms and blood samples for biomarker analysis will be collected.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Males or females ≥50 years of age
  • DSM-5 criteria for major or mild neurocognitive disorder due to AD or mixed AD/vascular disease
  • Mild severity of impairment (standardized Mini-Mental State Examination (MMSE) score ≥19)
  • Read and communicate in English
Exclusion Criteria
  • Change in cognitive enhancing medications (ChEIs and/or memantine) less than 3 months prior to study screen
  • Change in anticonvulsants or psychotropic medications less than 1 month prior to study screen
  • Currently taking benzodiazepines
  • Presence of metal implants that would preclude safe use of tDCS (e.g. pace-maker)
  • Significant neurological condition (e.g. epilepsy, Parkinson's disease, multiple sclerosis)
  • Current psychiatric disorders (e.g. schizophrenia, bipolar disorder, depression, psychosis) or current substance use disorder
  • Medical contraindications to increasing activity level according to the Canadian Society of Exercise Physiology Questionnaire

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Exercise and Sham tDCSSham tDCSPatients randomized to this group will attend TRI-UHN for an individualized exercise program and sham tDCS intervention.
Exercise and tDCStDCSPatients randomized to this group will attend Toronto Rehabilitation Institute - University Health Network (TRI-UHN) for an individualized exercise program and active tDCS intervention.
Exercise and tDCSExercisePatients randomized to this group will attend Toronto Rehabilitation Institute - University Health Network (TRI-UHN) for an individualized exercise program and active tDCS intervention.
Exercise Education and tDCStDCSPatients randomized to this group will undergo treatment as usual, receiving routine advice about physical activity and active tDCS intervention.
Exercise Education and tDCSExercise EducationPatients randomized to this group will undergo treatment as usual, receiving routine advice about physical activity and active tDCS intervention.
Exercise and Sham tDCSExercisePatients randomized to this group will attend TRI-UHN for an individualized exercise program and sham tDCS intervention.
Primary Outcome Measures
NameTimeMethod
Change in cognition: The Word Recognition Task from the Alzheimer's Disease Assessment Scale Cog (ADAS-Cog)Change over 2 weeks (Baseline to Endpoint)

Assess recognition memory. Words incorrectly recognized will be tallied. Word Recognition scores range from 0 to 12. Higher scores represent a worse outcome.

Secondary Outcome Measures
NameTimeMethod
Change in cognition: n-back reaction timeChange over 2 weeks (Baseline to Endpoint)

A measure of working memory. Reaction times in milliseconds will be recorded. Higher values represent a worse outcome.

Change in global cognitive function: The Montreal Cognitive Assessment (MoCA) Total ScoresChange over 2 weeks Baseline to Endpoint

A brief measure of global cognition that includes assessments of orientation, short-term total memory, executive function, language abilities, attention and visuospatial ability. MoCA scores range from 0 to 30. Higher scores represent a better outcome.

Change in cognition: The Word Recall Task from the Alzheimer's Disease Assessment Scale-Cog (ADAS-Cog)Change over 2 weeks (Baseline to Endpoint)

Assesses recall memory. Number of words not recalled will be tallied. Word recall scores range from 0 to 10. Higher scores represent a worse outcome.

Change in neuropsychiatric symptoms: The Neuropsychiatric Inventory (NPI)Change over 2 weeks (Baseline to Endpoint)

A widely used assessment of behavior disturbances in dementia including: apathy, agitation, delusions, hallucinations, depression, euphoria, aberrant motor behavior, irritability, disinhibition, anxiety, sleeping, and eating. Frequency and severity of each symptom is measured using subscales. Frequency and severity are judged using a 4-point scale (ranging from 1-4) and 3-point scale (ranging from 1-3) respectively. A 6-point scale for each symptom is used to evaluate caregiver distress (ranging from 0-5). Higher values represent a worse outcome.

Trial Locations

Locations (1)

Sunnybrook Health Sciences Centre

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath